plekha8 Antibody

What is the expected molecular weight for PLEKHA8 in Western blotting experiments?

PLEKHA8 has a calculated molecular weight of approximately 58 kDa, but the observed molecular weight can vary between 49-58 kDa and 65 kDa in Western blot applications . This variation may be due to post-translational modifications, protein isoforms, or tissue-specific differences in expression. When conducting Western blot experiments:

• Use appropriate positive controls (e.g., mouse brain tissue) which has been validated for PLEKHA8 detection

• Include molecular weight markers to accurately identify your protein of interest

• Be aware that different antibodies may detect slightly different molecular weights depending on the epitope recognized

What are the recommended applications for PLEKHA8 antibodies?

Based on the validation data available, PLEKHA8 antibodies are primarily suitable for:

• Western Blot (WB): Recommended dilution of 1:500-1:1000

• Immunohistochemistry (IHC): Recommended dilution of 1:20-1:200

• ELISA: Typical dilution of 1:1,000

The antibody effectiveness has been demonstrated across multiple species including human, mouse, and rat samples . When designing experiments, it's advisable to perform preliminary titration experiments to determine optimal antibody concentration for your specific application and sample type.

What are the optimal storage conditions for PLEKHA8 antibodies?

For maximum stability and performance, PLEKHA8 antibodies should be:

• Stored at -20°C for long-term storage

• Aliquoted to avoid repeated freeze-thaw cycles which can diminish antibody performance

• Stored in appropriate buffer conditions (typically PBS with 0.02% sodium azide and 50% glycerol at pH 7.3)

Most commercial antibodies remain stable for approximately one year after shipment when properly stored . For smaller volume antibodies (e.g., 20μl sizes), some manufacturers include 0.1% BSA as a stabilizing agent, which eliminates the need for aliquoting when stored at -20°C .

How should antigen retrieval be optimized for PLEKHA8 immunohistochemistry?

Successful IHC staining for PLEKHA8 requires careful attention to antigen retrieval methods:

Methodological considerations:

• Perform comparative analysis using both retrieval methods on your specific tissue samples

• Human kidney tissue has been validated as a positive control for IHC applications

• Optimize incubation times and temperatures based on your specific tissue thickness and fixation conditions

• Consider automated antigen retrieval systems for more consistent results across experiments

What validation approaches are recommended to confirm PLEKHA8 antibody specificity?

Multiple validation approaches should be employed to ensure antibody specificity:

• Knockdown/Knockout Validation: Several publications have utilized PLEKHA8 knockdown or knockout models to validate antibody specificity . This provides the most stringent control for antibody specificity.

• Peptide Competition Assay: Pre-incubate the antibody with the immunizing peptide (where available) to block specific binding sites.

• Cross-Reactivity Testing: Test the antibody against recombinant PLEKHA8 protein (e.g., ABIN7554971 recombinant protein, AA 1-519) to confirm specific recognition.

• Tissue Panel Validation: Compare staining patterns across multiple tissue types known to express PLEKHA8 at different levels.

• Western Blot Analysis: Confirm that the antibody detects bands of the expected molecular weight (49-65 kDa range) .

How can epitope considerations impact experimental design when using PLEKHA8 antibodies?

Different commercial antibodies target various epitopes of the PLEKHA8 protein, which can significantly impact experimental outcomes:

• C-terminal targeting antibodies: Some antibodies specifically target the C-terminal region (amino acids 455-482) , which may not detect truncated variants or splice isoforms lacking this region

• Full-length protein recognition: Antibodies raised against full-length proteins may provide broader detection capabilities

• Phosphorylation-dependent epitopes: Consider whether post-translational modifications might affect epitope accessibility

When designing critical experiments, consider using multiple antibodies targeting different epitopes to ensure comprehensive detection of all relevant PLEKHA8 protein forms.

What are the recommended protocols for detecting PLEKHA8 in different cellular compartments?

PLEKHA8/FAPP2 localizes primarily to the trans-Golgi network, but its detection requires specific considerations:

For Immunofluorescence Applications:

• Recommended concentration: 0.25-2 μg/mL

• Fixation method: 4% paraformaldehyde is generally preferred over methanol fixation

• Permeabilization: Use 0.1% Triton X-100 or 0.1% saponin to ensure access to intracellular compartments

• Co-staining: Consider using established Golgi markers (e.g., GM130, TGN46) for colocalization studies

• Confocal microscopy: Necessary for accurate subcellular localization assessment

Troubleshooting tip: If background staining is high, implement additional blocking steps using sera from the same species as the secondary antibody.

How should researchers interpret conflicting results between different detection methods for PLEKHA8?

Discrepancies between detection methods (e.g., Western blot vs. IHC vs. IF) may arise from several factors:

• Protein conformation differences: Native protein in IF may present different epitopes than denatured protein in WB

• Cross-reactivity issues: Some antibodies may cross-react with related pleckstrin homology domain proteins

• Isoform-specific detection: Different detection methods may preferentially detect certain isoforms

• Method-specific artifacts: Fixation can alter epitope accessibility in IF/IHC

Resolution approach:

• Validate findings using multiple antibodies targeting different epitopes

• Employ genetic approaches (siRNA, CRISPR) to confirm specificity

• Consider native vs. denaturing conditions when interpreting results

• Document all experimental conditions meticulously for reproducibility

What controls are essential when studying PLEKHA8 in functional assays?

When designing functional studies involving PLEKHA8:

Essential Controls for Knockdown/Overexpression Studies:

• Scrambled siRNA/shRNA controls for knockdown experiments

• Empty vector controls for overexpression studies

• Rescue experiments using siRNA-resistant constructs

• Expression level quantification by both protein (Western blot) and mRNA (qPCR) analyses

Functional Assay-Specific Controls:

• For Golgi trafficking studies: Use established cargo proteins with well-characterized transport kinetics

• For protein-protein interaction studies: Include non-interacting protein controls

• For subcellular localization: Include co-staining with established compartment markers

How is PLEKHA8/FAPP2 implicated in disease processes?

Recent research has identified PLEKHA8/FAPP2 involvement in several pathological processes:

• Cancer progression: Published findings indicate FAPP2 promotes tumor cell growth in human colon cancer through activation of Wnt signaling pathways

• Lipid metabolism disorders: As a lipid transfer protein, PLEKHA8 dysfunction may contribute to disorders of lipid metabolism

• Membrane trafficking defects: Given its role in Golgi-to-plasma membrane transport, dysfunction may impact secretory pathways

Researchers investigating disease associations should consider:

• Tissue-specific expression patterns

• Interaction with known disease-associated proteins

• Genetic variations (SNPs) in the PLEKHA8 gene and their clinical correlations

What are the most appropriate model systems for studying PLEKHA8 function?

Selecting appropriate model systems is crucial for PLEKHA8 functional studies:

For advanced functional studies, consider:

• Primary cell cultures from relevant tissues

• Organoid models for 3D tissue organization

• Conditional knockout mouse models for temporal control of PLEKHA8 deletion

• CRISPR-based genome editing for introducing specific mutations or tags

How can researchers effectively study PLEKHA8 protein-protein interactions?

To investigate PLEKHA8 interactions with binding partners:

• Co-immunoprecipitation (Co-IP): Select antibodies that don't interfere with protein interaction domains. The affinity-isolated antibodies (such as HPA072314) are suitable options.

• Proximity Ligation Assay (PLA): Particularly useful for detecting transient or weak interactions in fixed cells.

• FRET/BRET assays: For studying dynamic interactions in living cells.

• Recombinant protein approaches: The availability of purified recombinant PLEKHA8 protein (AA 1-519) enables in vitro binding assays.

• Domain mapping: The pleckstrin homology domain is critical for phosphoinositide binding; consider domain-specific mutations to disrupt specific interactions.

Methodological tip: When designing tagged PLEKHA8 constructs, carefully consider tag position to avoid disrupting functional domains, particularly the N-terminal pleckstrin homology domain and C-terminal regions involved in protein-protein interactions.

What are the considerations when using PLEKHA8 viral vectors for functional studies?

When utilizing viral vectors for PLEKHA8 studies (such as AAV vectors) :

• Serotype selection: Different AAV serotypes have varying tropism for different cell types. Consult serotype selection guidelines for your target tissue/cell type.

• Promoter selection: The CMV promoter is commonly used , but tissue-specific promoters may be more appropriate for certain applications.

• Expression verification: Confirm successful transduction and expression using both RT-qPCR and Western blot analysis.

• Functional assessment: Design appropriate assays to assess changes in Golgi morphology, trafficking rates, or lipid distribution.

For in vivo studies, consider:

• Purification grade of viral preparations (especially for in vivo applications)

• Expression kinetics (typically observable 48 hours up to 5 days post-infection)

• Potential immune responses to viral capsids in animal models

How do I select the most appropriate antibody format for specific PLEKHA8 applications?

Different experimental applications may require specific antibody formats:

When selecting PLEKHA8 antibodies:

• Consider polyclonal antibodies for maximum epitope coverage (such as rabbit polyclonal antibodies)

• For reproducibility across long-term studies, monoclonal antibodies may offer more consistent lot-to-lot performance

• Affinity-isolated antibodies may provide enhanced specificity for challenging applications

What methodological approaches can resolve discrepancies in observed molecular weights for PLEKHA8?

The observed molecular weight variation for PLEKHA8 (49-65 kDa) can complicate data interpretation. To address this:

• Isoform analysis: Use RT-PCR to identify which PLEKHA8 isoforms are expressed in your experimental system.

• Post-translational modification assessment:

  • Phosphatase treatment to identify phosphorylation contributions

  • Glycosidase treatment to assess glycosylation impacts

  • Ubiquitination analysis for higher molecular weight forms

• Sample preparation optimization:

  • Compare different lysis buffers (RIPA vs. NP-40 vs. Triton X-100)

  • Evaluate protease inhibitor effectiveness

  • Test different reducing agent concentrations

• Technical validation:

  • Use recombinant PLEKHA8 protein as a size standard

  • Compare results across different percentage gels

  • Consider gradient gels for better resolution